Why CODE matters
Harnessing Europe’s anti-cancer medicine usage data
There is an enormous effort driving innovation in anti-cancer medicines, yet surprisingly little is known about how different drugs are being used in clinical practice today.
The Collaboration for Oncology Data in Europe (CODE) aims to expand our knowledge of anti-cancer medicines use, by supporting the development of a dedicated Oncology Data Network. The data collated will enable the oncology community to derive greater value from anti-cancer medicines for patients.
The technology platform that underpins the Data Network is custom designed with the security and scale needed for the objectives of CODE. It has been conceived to be able to aggregate data for all forms of cancer, in all patients at Europe’s cancer treatment centres, in near real-time, on how anti-cancer medicines are being used in today’s clinical practice, in which patient groups and in which combinations and sequences.
The aim is to collaborate with 200 cancer treatment centres in seven European countries in the first three years, scaling to an estimated 2,000 treatment centres across Europe over 10 years.
Why we matter to oncologists
Oncologists can use the near real time analyses provided via the Oncology Data Network to reflect on their own practice and insights from others in the network in an increasingly specialised clinical environment
Why we matter to pharmacists
The Oncology Data Network will give pharmacists access to information from their own centres as well as insights from others in the network, which will directly support them in their role as an oncology pharmacist
Why we matter to healthcare systems
The data collected through the Oncology Data Network will provide valuable information on how anti-cancer medicines are being used in clinical practice today, which can be used by decision-makers to help derive the full value from these therapies
Why we matter for patients
The information made available through the Oncology Data Network will provide valuable information into how patients are currently treated and patients’ access to anti-cancer medicines. Over time, CODE can play a role in facilitating patient access to innovative therapies